Ligand Pharmaceuticals (LGND) Other Non Operating Income (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Other Non Operating Income data on file, last reported at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income fell 365.24% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$335000.0 (up 96.2% YoY), and the FY2025 full-year result was -$89000.0, up 99.41% from the prior year.
• Other Non Operating Income fell to -$1.2 million in Q1 2026, from -$89000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $2.3 million in Q1 2022 to a low of -$7.8 million in Q3 2024.
• A 5-year average of -$939923.1 and a median of -$443000.0 in 2025 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income jumped 321.65% in 2022 and plunged 365.24% in 2026, its largest moves.
• Tracing LGND's Other Non Operating Income over 5 years: stood at -$5.0 million in 2022, then surged by 82.47% to -$873000.0 in 2023, then slumped by 66.09% to -$1.4 million in 2024, then jumped by 93.86% to -$89000.0 in 2025, then tumbled by 1220.22% to -$1.2 million in 2026.
• Business Quant data shows LGND's Other Non Operating Income at -$1.2 million in Q1 2026, -$89000.0 in Q4 2025, and -$443000.0 in Q3 2025.